CENTRE ANTOINE LACASSAGNE

Their core work

Centre Antoine Lacassagne is a comprehensive cancer treatment and research centre in Nice, France, specializing in radiation oncology. Their H2020 work reflects two distinct but complementary clinical and technical roles: contributing medical physics expertise to a project developing optical fibre dosimetry tools for brachytherapy (ORIGIN), and serving as a clinical trial site in a major comparative study of proton versus photon radiotherapy for esophageal cancer (PROTECT-trial). As a cancer centre rather than a university, they bring real patient cohorts and clinical protocols to research consortia — a contribution that basic research groups cannot replicate. Their value lies in bridging advanced radiation physics with actual oncology practice.

What they specialise in

How they've shifted over time

Their first H2020 project (ORIGIN, starting 2020) placed them in a medical physics and instrumentation context — developing better dosimetry tools for brachytherapy, a technically demanding internal radiotherapy method. Their second project (PROTECT-trial, starting 2021) shifted focus toward large-scale clinical comparison: proton therapy versus conventional photon radiotherapy for a specific cancer type. This signals a move from technology development support toward clinical evidence generation, which is a natural evolution for a treatment centre building its research portfolio. The trajectory suggests increasing engagement with comparative effectiveness research and potentially with high-cost therapy modalities like proton therapy.

The centre appears to be positioning itself as a clinical evidence hub for advanced radiotherapy modalities, moving from technical instrumentation projects toward randomised trial participation — a path that typically increases both reputation and future funding eligibility.

How they like to work

Centre Antoine Lacassagne has participated in both H2020 projects as a partner, never as coordinator — consistent with a clinical institution that contributes patient access, clinical protocols, and domain expertise rather than administrative or scientific leadership. Despite having only two projects, they have accumulated 28 distinct consortium partners across 10 countries, suggesting they join large, multi-site research consortia where their clinical role is specific and valued. Partners considering them should expect a well-defined specialist contribution, not broad project management capacity.

With 28 unique partners across 10 countries from just two projects, the centre has a surprisingly wide network relative to its H2020 footprint — both projects appear to be large multi-partner consortia. Their European reach is established, though their geographic depth outside France is not yet clear from this data alone.

What sets them apart

Unlike university-based research groups, Centre Antoine Lacassagne offers what many consortia need but struggle to find: a functioning clinical cancer centre willing to enrol patients and apply new technologies in real treatment settings. Their combination of brachytherapy infrastructure and apparent proton therapy access makes them particularly valuable for projects that need to demonstrate clinical feasibility, not just laboratory proof-of-concept. For any consortium working on radiation therapy technology — dosimetry, treatment planning, or therapy comparison — they bring genuine translational credibility.

Highlights from their portfolio

• PROTECT-trial
  A long-running (2021–2027) randomised clinical trial comparing proton and photon therapy for esophageal cancer — one of the most resource-intensive project types in oncology research, and the centre's largest EC-funded engagement.
• ORIGIN
  An unusual cross-sector project combining optical fibre sensing technology with adaptive brachytherapy dosimetry, linking digital instrumentation and clinical radiation oncology.